US4616023A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions of 4-(dibenzo-[a,d]cycloalkenyl)piperazine compounds and methods
Assignee: Merck and Co Inc
•
Filing: 1985-02-21
•
Granted: 1986-10-07
•
Expires: 2005-02-21
Abstract
Abstract Pharmaceutical compositions comprising 4-(dibenzo[a,d]cycloalkenyl)piperazine compounds and the use of said piperazine compounds for treatment of certain cardiovascular disorders are disclosed.
Inventors
- 👤 David C. Remy
- 👤 Steven D. Young
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 20:44
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/04; C07D295/06; C07D295/073; A; A61; A61K; A61K31/00; C07D295/08; C07D295/084; C07D295/088; C07D295/096; C07D295/16; C07D295/20; C07D295/205
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
71 words
A composition useful for the treatment of cardiovascular disorders caused by high cellular concentration of Ca ++ comprising a therapeutically effective amount of a compound having the formula: ##STR20## wherein X is hydrogen, halogen, lower alkoxy, lower alkylthio, lower alkylsulfonyl, or trifluoromethyl, R is cinnamyl, lower alkoxycinnamyl, cinnamoyl, lower alkoxycinnamoyl, lower hydroxyalkyl or carbalkoxy; or a pharmaceutically acceptable acid addition salt thereof; said compound in admixture with a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
71 words
A composition useful for the treatment of cardiovascular disorders caused by high cellular concentration of Ca ++ comprising a therapeutically effective amount of a compound having the formula: ##STR20## wherein X is hydrogen, halogen, lower alkoxy, lower alkylthio, lower alkylsulfonyl, or trifluoromethyl, R is cinnamyl, lower alkoxycinnamyl, cinnamoyl, lower alkoxycinnamoyl, lower hydroxyalkyl or carbalkoxy; or a pharmaceutically acceptable acid addition salt thereof; said compound in admixture with a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
11 words
A composition according to claim 1 wherein the compound is 1-cinnamyl-4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperazine.
Claim 4
Independent Claim
71 words
A method for treating cardiovascular disorders caused by high cellular concentration of Ca ++ comprising administering to a patient in need of such treatment, a therapeutically effective amount of a compound having the formula: ##STR21## wherein X is hydrogen, halogen, lower alkoxy, lower alkylthio, lower alkylsulfonyl, or trifluoromethyl, R is hydrogen, lower alkyl, cinnamyl, lower alkoxycinnamyl, cinnamoyl, lower alkoxycinnamoyl, lower hydroxyalkyl, or carbalkoxy; or a pharmaceutically acceptable acid addition salt thereof.
Claim 5
Independent Claim
71 words
A method for treating cardiovascular disorders caused by high cellular concentration of Ca ++ comprising administering to a patient in need of such treatment, a therapeutically effective amount of a compound having the formula: ##STR21## wherein X is hydrogen, halogen, lower alkoxy, lower alkylthio, lower alkylsulfonyl, or trifluoromethyl, R is hydrogen, lower alkyl, cinnamyl, lower alkoxycinnamyl, cinnamoyl, lower alkoxycinnamoyl, lower hydroxyalkyl, or carbalkoxy; or a pharmaceutically acceptable acid addition salt thereof.
Claim 6
Dependent Claim
13 words
The method according to claim 3 wherein the compound is 1-(3-bromo-5H-dibenzo a,d, cyclohepten-5-yl)-4-methylpiperazine.
Claim 7
Dependent Claim
13 words
The method according to claim 3 wherein the compound is 1-(3-chloro-5H-dibenzo a,d -cyclohepten-5-yl)-4-methylpiperazine.
Claim 8
Dependent Claim
20 words
The method according to claim 3 wherein the compound is one in which X is alkoxy and R is methyl.
Claim 9
Dependent Claim
11 words
The method according to claim 6 wherein the compound is 1-(3-methoxy-5H-dibenzo[a,d]cyclohepten-5-yl)-4-methylpiperazine.
Claim 10
Dependent Claim
20 words
The method according to claim 3 wherein the compound is one in which X is alkylthio and R is methyl.
Claim 11
Dependent Claim
11 words
The method according to claim 8 wherein the compound is 1-methyl-4-(3-methylthio-5H-dibenzo[a,d]-cyclohepten-5-yl)piperazine.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-10-06 | 1990-04-07 | 1990-10-07 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-10-06 | 1994-04-07 | 1994-10-07 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-10-06 | 1998-04-07 | 1998-10-07 | $7700.00 | Window Closed / Lapsed |